Key facts
- It has raised $23.8M; the latest was Later Stage VC ($13.8M) in Nov 2025.
- Notable investors include United States Department of War.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Phoenicis
- ·The full record, as it builds
Funding rounds
No funding rounds for Phoenicis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phoenicis
Provider of therapies and treatment services based in Hingham, United States. The company offers treatments for rare, genetic, and inflammatory disorders, with multiple potential therapies, enabling children, including orphans, and those with pediatric designations to access a cure for their ailment without worrying about cost.
- Sector
- Healthcare
- HQ
- Hingham, MA, United States
- Founded
- 2020
- Website
- phoenicistx.com/
- Ownership
- Privately Held (backing)
Phoenicis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phoenicis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phoenicis in its N-PORT filings yet. We sweep new filings monthly.